Zealand Pharma Unveils Metabolic Frontier 2030 Strategy
11 Dec 2025 //
GLOBENEWSWIRE
Ascletis Chooses ASC36, A Monthly Subcutaneous Amylin Agonist
30 Oct 2025 //
PR NEWSWIRE
Zealand Pharma May Sell Future Obesity Drug Direct to Patients
23 Sep 2025 //
REUTERS

Market Place
Sourcing Support